MedTrace Logo

Study of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency)

NCT01475578 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2011-11-21

No results posted yet for this study

Summary

The objectives of this phase II study of STA-1 capsule was to make preliminary evaluation on clinical efficacy and safety of STA-1 capsule in order that based on the dosage and study structure planned in this project, the dosage and study structure of phase III study can be confirmed.

Conditions

  • Vascular Dementia

Interventions

DRUG

STA-1

STA-1 capsule (manufactured by Sinphar Tian-Li (Hangzhou) Pharm. Co., Ltd.; Batch number: 020121), 2 capsules/time, 3 times/day, orally

DRUG

Ergoloid Mesylates tablet

Ergoloid Mesylates tablet (manufactured by Tianjin Huajin Pharmaceutical Factory; Batch number: 011230), 2 tablets/time, 3 times/day, orally before meal

Sponsors & Collaborators

  • Sinphar Pharmaceutical Co., Ltd

    lead OTHER

Principal Investigators

  • Mingjun Yang · Affiliated Hospital of Chengdu University of Traditional Chinese Medicines

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-03-31
Primary Completion
2002-10-31
Completion
2002-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01475578 on ClinicalTrials.gov